Tandem’s tslim:X2 Pump OK’ed with Lilly’s Lyumjev Insulin in EU

Tandem Diabetes Care revealed that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) system is now cleared for use with Eli Lilly and Company’s Lyumjev ultra-rapid acting insulin in the EU.
 
Lyumjev was authorized for general use in insulin pumps in the EU in 2020, but pump manufacturers are required to perform extensive testing to verify compatibility with individual insulin pumps and AID systems.
 
Tandem and Lilly partnered to support a clinical trial demonstrating the benefits of using Lyumjev with Control-IQ. The duo is continuing to work to secure Lyumjev compatibility for the t:slim X2 pump in other regions and gained Lyumjev compatibility with the Tandem Mobi pump. 

---

READ MORE: Tandem Diabetes Rolls Out Mobi Automated Insulin Pump in U.S.

---

“High satisfaction and quality of life benefits were recently shown in a clinical study using Lyumjev with Control-IQ technology,” said Jordan Pinsker, MD, chief medical officer at Tandem Diabetes Care. “Ultra-rapid acting insulin is a popular choice for people living with diabetes due to its fast response time. We are proud to be able to offer Lyumjev compatibility with our t:slim X2 pump as part of an AID system in the EU, providing more flexibility for our customers in these countries.”
 
The t:slim X2 pump is currently cleared for use with Humalog and Novolog/NovoRapid U-100 insulins globally, and Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi U-100 insulins in Canada and selected EU countries.